Induction of CD83+CD14+ nondendritic antigen-presenting cells by exposure of monocytes to IFN-α1

Journal of Immunology

Volumn 181, Issue 5, 2008, Pages 2999-3008

  Gerlini, Gianni ^a,b   Mariotti, Giulia ^b   Chiarugi, Alberto ^b   Di Gennaro, Paola ^b   Caporale, Roberto ^b   Parenti, Astrid ^b   Cavone, Leonardo ^b   Tun Kyi, Adrian ^c   Prignano, Francesca ^b   Saccardi, Riccardo ^b   Borgognoni, Lorenzo ^a   Pimpinelli, Nicola ^b  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD14 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CELL MARKER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; STAT1 PROTEIN; TETANUS TOXOID; BIOLOGICAL MARKER; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD SAMPLING; CELL DIFFERENTIATION; CELL STIMULATION; CELL STRUCTURE; CHICKENPOX; DENDRITIC CELL; EXPOSURE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IN VITRO STUDY; INFECTION; MEMORY T LYMPHOCYTE; MIXED LYMPHOCYTE REACTION; MONOCYTE; NEOPLASM; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION; CD4+ T LYMPHOCYTE; DRUG EFFECT; IMMUNOLOGICAL MEMORY; IMMUNOLOGY;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD80; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CHICKENPOX; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC MEMORY; INTERFERON-ALPHA; MEMBRANE GLYCOPROTEINS; MONOCYTES;

EID: 51549085069     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.5.2999     Document Type: Article

References (58)

1. Cella, M., F. Sallusto, and A. Lanzavecchia. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9: 10-16. (Pubitemid 27095893)
2. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
3. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767-811.
4. Zhou, L. J., and T. F. Tedder. 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 154: 3821-3835.
5. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179: 1109-1118. (Pubitemid 24091769)
6. Romani, N., D. Reider, M. Heuer, S. Ebner, E. Kampgen, B. Eibl, D. Niederwieser, and G. Schuler. 1996. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J. Immunol. Methods 196: 137-151. (Pubitemid 26306735)
7. Timmerman, J. M., and R. Levy. 1999. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50: 507-529. (Pubitemid 29117080)
8. Fong, L., and E. G. Engleman. 2000. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18: 245-273.
9. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328-332. (Pubitemid 28144092)
10. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2: 52-58.
11. Cella, M., D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajima, A. Lanzavecchia, and M. Colonna. 1999. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5: 919-923. (Pubitemid 29372419)
12. Siegal, F. P., N. Kadowaki, M. Shodell, P. A. Fitzgerald-Bocarsly, K. Shah, S. Ho, S. Antonenko, and Y. J. Liu. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284: 1835-1837. (Pubitemid 29275623)
13. + blood dendritic cells are potent producers of IFN-alpha in response to in vitro HIV-1 infection. J. Immunol. 152: 4649-4662.
14. Corssmit, E. P., J. de Metz, H. P. Sauerwein, and J. A. Romijn. 2000. Biologic responses to IFN-α administration in humans. J. Interferon Cytokine Res. 20: 1039-1047.
15. Belardelli, F., and M. Ferrantini. 2002. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 23: 201-208. (Pubitemid 34260936)
16. Schalm, S., R. De Man, and H. Janssen. 2002. Combination and newer therapies for chronic hepatitis B. J. Gastroenterol. Hepatol. 17 (Suppl. 3): S338-S341. (Pubitemid 35454307)
17. Luxon, B. A., M. Grace, D. Brassard, and R. Bordens. 2002. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin. Ther. 24: 1363-1383. (Pubitemid 35176970)
18. Kirkwood, J. 2002. Cancer immunotherapy: the interferon-α experience. Semin. Oncol. 29: 18-26.
19. Agarwala, S. S., and J. M. Kirkwood. 2002. Update on adjuvant interferon therapy for high-risk melanoma. Oncology 16: 1177-1187.
20. Olsen, E. A. 2003. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol. Ther. 16: 311-321. (Pubitemid 38044675)
21. Radvanyi, L. G., A. Banerjee, M. Weir, and H. Messner. 1999. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand. J. Immunol. 50: 499-509.
22. McRae, B. L., T. Nagai, R. T. Semnani, J. M. van Seventer, and G. A. van Seventer. 2000. Interferon-α and -β inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14+ precursors. Blood 96: 210-217. (Pubitemid 30456473)
23. Luft, T., K. C. Pang, E. Thomas, P. Hertzog, D. N. Hart, J. Trapani, and J. Cebon. 1998. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161: 1947-1953. (Pubitemid 28387618)
24. + effector T cells. J. Leukocyte Biol. 71: 669-676.
25. Santini, S. M., C. Lapenta, M. Logozzi, S. Parlato, M. Spada, T. Di Pucchio, and F. Belardelli. 2000. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191: 1777-1788.
26. Paquette, R. L., N. C. Hsu, S. M. Kiertscher, A. N. Park, L. Tran, M. D. Roth, and J. A. Glaspy. 1998. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukocyte Biol. 64: 358-367. (Pubitemid 28409243)
27. Parlato, S., S. M. Santini, C. Lapenta, T. Di Pucchio, M. Logozzi, M. Spada, A. M. Giammarioli, W. Malorni, S. Fais, and F. Belardelli. 2001. Expression of CCR-7, MIP-3β, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98: 3022-3029.
28. McRae, B. L., R. T. Semnani, M. P. Hayes, and G. A. van Seventer. 1998. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J. Immunol. 160: 4298-4304.
29. Lehner, M., T. Felzmann, K. Clodi, and W. Holter. 2001. Type I interferons in combination with bacterial stimuli induce apoptosis of monocyte-derived dendritic cells. Blood 98: 736-742.
30. Bukowski, R. M., C. Tendler, D. Cutler, E. Rose, M. M. Laughlin, and P. Statkevich. 2002. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-α-2b formulation. Cancer 95: 389-396.
31. Corssmit, E. P., R. Heijligenberg, C. E. Hack, E. Endert, H. P. Sauerwein, and J. A. Romijn. 1997. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin. Exp. Immunol. 107: 359-363.
32. Cella, M., F. Facchetti, A. Lanzavecchia, and M. Colonna. 2000. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat. Immunol. 1: 305-310.
33. Grunfeld, C., D. P. Kotler, J. K. Shigenaga, W. Doerrler, A. Tierney, J. Wang, R. N. Pierson, Jr., and K. R. Feingold. 1991. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 90: 154-162.
34. Gerlini, G., G. Mariotti, B. Bianchi, and N. Pimpinelli. 2006. Massive recruitment of type I interferon producing plasmacytoid dendritic cells in varicella skin lesions. J. Invest. Dermatol. 126: 507-509. (Pubitemid 43323190)
35. Fah, J., J. Pavlovic, and G. Burg. 1995. Expression of MxA protein in inflammatory dermatoses. J. Histochem. Cytochem. 43: 47-52.
36. high) dendritic cells in human nasal allergy. J. Immunol. 165: 4062-4068.
37. Ito, T., R. Amakawa, M. Inaba, S. Ikehara, K. Inaba, and S. Fukuhara. 2001. Differential regulation of human blood dendritic cell subsets by IFNs. J. Immunol. 166: 2961-2969. (Pubitemid 33117291)
38. Paquette, R. L., N. Hsu, J. Said, M. Mohammed, N. P. Rao, G. Shih, G. Schiller, C. Sawyers, and J. A. Glaspy. 2002. Interferon-α induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia 16: 1484-1489.
39. Blanco, P., A. K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294: 1540-1543. (Pubitemid 33063928)
40. + dendritic cells. Eur. J. Immunol. 33: 358-367.
41. Ozer, H., S. L. George, C. A. Schiffer, K. Rao, P. N. Rao, D. H. Wurster-Hill, D. D. Arthur, B. Powell, A. Gottlieb, B. A. Peterson, et al. 1993. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 82: 2975-2984. (Pubitemid 23334922)
42. Sawyers, C. L. 1999. Chronic myeloid leukemia. N. Engl. J. Med. 340: 1330-1340.
43. Molldrem, J. J., P. P. Lee, S. Kant, E. Wieder, W. Jiang, S. Lu, C. Wang, and M. M. Davis. 2003. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111: 639-647.
44. Wetzler, M., H. Kantarjian, R. Kurzrock, and M. Talpaz. 1995. Interferon-alpha therapy for chronic myelogenous leukemia. Am. J. Med. 99: 402-411.
45. Kirkwood, J. M., M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden, and R. H. Blum. 1996. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14: 7-17.
46. + T cell development in the thymus. Cell 108: 755-767.
47. Lechmann, M., D. J. Krooshoop, D. Dudziak, E. Kremmer, C. Kuhnt, C. G. Figdor, G. Schuler, and A. Steinkasserer. 2001. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J. Exp. Med. 194: 1813-1821. (Pubitemid 34028660)
48. Kruse, M., O. Rosorius, F. Kratzer, G. Stelz, C. Kuhnt, G. Schuler, J. Hauber, and A. Steinkasserer. 2000. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J. Virol. 74: 7127-7136. (Pubitemid 30470697)
49. + T cells is regulated by virus-induced, soluble-mediator-dependent maturation of dendritic cells. J. Virol. 76: 142-150.
50. Lechmann, M., S. Berchtold, J. Hauber, and A. Steinkasserer. 2002. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. 23: 273-275. (Pubitemid 34628763)
51. Nestle, F. O., X. G. Zheng, C. B. Thompson, L. A. Turka, and B. J. Nickoloff. 1993. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J. Immunol. 151: 6535-6545.
52. Gerlini, G., H. P. Hefti, M. Kleinhans, B. J. Nickoloff, G. Burg, and F. O. Nestle. 2001. CD1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells. J. Invest. Dermatol. 117: 576-582. (Pubitemid 32955583)
53. + cells differentiate into Langerhans cells. Nat. Immunol. 2: 1151-1158.
54. + cells in human dermal cell suspensions. Identification of a small subset responsible for potent dermal antigen-presenting cell activity with features analogous to Langerhans cells. J. Immunol. 151: 4067-4080.
55. Girard, J. P., and T. A. Springer. 1995. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol. Today 16: 449-457.
56. Giuffre, L., A. S. Cordey, N. Monai, Y. Tardy, M. Schapira, and O. Spertini. 1997. Monocyte adhesion to activated aortic endothelium: role of L-selectin and heparan sulfate proteoglycans. J. Cell Biol. 136: 945-956. (Pubitemid 27098749)
57. Li, J., A. I. Colovai, R. Cortesini, and N. Suciu-Foca. 2000. Cloning and functional characterization of the 5′-regulatory region of the human CD86 gene. Hum. Immunol. 61: 486-498. (Pubitemid 30238279)
58. Tomic, J., D. White, Y. Shi, J. Mena, C. Hammond, L. He, R. L. Miller, and D. E. Spaner. 2006. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J. Immunol. 176: 3830-3839. (Pubitemid 43364032)